COMPARATIVE STUDY OF SAFETY AND EFFICACY OF AZITHROMYCIN AND AMOXICILLIN IN TREATING CHILDREN WITH LOWER RESPIRATORY TRACT INFECTION
Objectives: Lower respiratory infections are common among school going children. Frequent infections are troublesome children and to their parents and may lead to respiratory complication such as Chronic Bronchitis, bronchiolitis and bronchial asthma. Frequent dropouts in schools and may affect the studies of the children. So there is a need of an effective and safe drug for the infection.
Methods: The study was with 40 patients of the age group between 1 to 12 years, who were diagnosed with the lower respiratory infection. The patients were divided in to two groups. Group A Amoxicillin group (n=40) was treated Amoxicillin with 40 mg/day. Group B Amoxicillin group (n=40) was treated 10 mg/day. Both the drugs were orally. Clinical evaluation of symptoms was assessed before and after treatment (3rd and 7th days). Patient's White Blood cell Counts, Lymphocytes counts were analyzed accordingly.
Results: At the end of the treatment (3rd and 7th days) the clinical evaluation, WBC and Lymphocytes count in Azithromycin group showed significant reduction of WBCs (12.1%) and Lymphocyte counts (8.2%) than amoxicillin group. Minimal adverse drug reactions were noted in Azithromycin group.
Conclusion: There is clear evidence that Azithromycin is superior to amoxicillin in treating lower respiratory infections in children.
2. Langtry HD, Balfour JA. Azithromycin: a review of its use in pediatric infectious diseases. Drugs 1998;56:273â€“97.
3. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750â€“9.
4. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991;91, Suppl 3A:12â€“8.
5. Lauvau DV, Verbist L. An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group. J Int Med Res 1997;25:285â€“95.
6. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994;3:266â€“73.
7. Behre U, Burow HM, Quinn P, Cree F, Harrison H. E Efficacy of twice-daily dosing of amoxicillin/clavulanate in acute otitis media in children. Infection 1997;25:163â€“6.
8. Machin D, Campbell M. Statistical tables for the design of clinical trials. Blackwell Scientific Publications, Oxford; 1987. p. 53.
9. Roord JJ, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective, open, randomized study comparing efficacies and safeties of a 3-day course of Azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob. Agents Chemother 1996;40:2765â€“8.
10. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996;37 Suppl:143â€“9.